21 results on '"Gao, Xiao-Ning"'
Search Results
2. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
- Author
-
Gao, Xiao-Ning, Su, Yong-Feng, Li, Meng-yue, Jing, Yu, Wang, Jun, Xu, Lei, Zhang, Lin-Lin, Wang, An, Wang, Yi-Zhi, Zheng, Xuan, Li, Yan-Fen, and Liu, Dai-Hong
- Subjects
DECITABINE ,ACUTE myeloid leukemia ,DRUG side effects ,PROGRAMMED cell death 1 receptors ,LUNG infections ,DNA ,T cells - Abstract
Anti-PD-1 monotherapy had limited clinical efficacy in relapsed/refractory (r/r) AML patients with higher PD-1 and PD-L1 expression. Hence, we investigated the efficacy and safety of PD-1 inhibitor with DNA hypomethylating agent (HMA) + CAG regimen in patients who had failed prior AML therapy. In this phase 2, single-arm study, r/r AML patients received azacitidine or decitabine plus CAG regimen with tislelizumab. Primary endpoints were efficacy (objective response rate [ORR]) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). Statistical analyses were performed using Stata 14.0 and SPSS 20.0 software where P < 0.05 denoted significance. Twenty-seven patients were enrolled patients and completed 1 cycle, and 14 (51.9%) and 4 (14.8%) patients completed 2 and 3 cycles, respectively. ORR was 63% (14: complete remission [CR]/CR with incomplete hematologic recovery [CRi], 3: partial remission (PR), 10: no response [NR]). Median OS (mOS) and EFS were 9.7 and 9.2 months, respectively. With a median follow-up of 8.2 months (1.1–26.9), the mOS was not reached in responders (CR/CRi/PR) while it was 2.4 months (0.0–5.4) in nonresponders (P = 0.002). Grade 2–3 immune-related adverse events (irAEs) were observed in 4 (14.8%) patients and 3 nonresponders died of lung infection after treatment. Tislelizumab + HMA + CAG regimen showed improved outcomes in r/r AML patients with lower pretherapy leukemia burden. irAEs were mild and low-grade and higher pretherapy bone marrow CD4
+ CD127+ PD-1+ T cells might serve as a predictor of treatment response. ClinicalTrials.gov identifier NCT04541277. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
- Author
-
Lu, Ning, Lin, Ji, Wang, Li-Li, Li, Yu-Yan, Wang, Li-Jun, Gao, Chun-Ji, Liu, Dai-Hong, and Gao, Xiao-Ning
- Abstract
To explore the efficacy and safety of G-SCF-mobilized donor lymphocyte infusion (DLI) for treatment of relapse of hematologic malignancies after allogeneic peripheral blood stem cell transplantation, we performed a retrospective analysis in a cohort of patients with morphologic (n = 36) or molecular (n = 22) relapse post transplantation. The 3-year post-DLI survival rates for therapeutic and preemptive DLI recipients were 16.7% and 33.3%, respectively. The occurrence of DLI-associated acute graft-versus-host disease predicted longer survival, whereas diagnosis of T cell acute lymphoblastic leukemia/lymphoma or myelodysplastic syndromes or early relapse after transplant (< 6 months) predicted shorter survival after therapeutic DLI. Cumulative incidence of progression to hematologic relapse and non-relapse mortality after preemptive DLI were 46.8% and 29.1%, respectively. Active disease prior to transplant and early molecular relapse after transplant (< 4 months) were the strongest predictors of non-relapse mortality after preemptive DLI. In conclusion, although therapeutic DLI had limited efficacy against T cell acute lymphoblastic leukemia/lymphoma or myelodysplastic syndromes or early post-transplant relapse, patients who developed DLI-associated acute graft-versus-host disease would benefit from this procedure in the setting of G-SCF-mobilized DLI. Furthermore, preemptive DLI could protect half of patients from hematologic relapse after transplantation with acceptable toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. The Relationship between HIF1α and WTAP Expression Level in t(8;21) Acute Myeloid Leukemia.
- Author
-
SHAO Yang-Liu, CHEN Zei, WANG Li-Li, LIU Dai-Hong, and GAO Xiao-Ning
- Published
- 2021
- Full Text
- View/download PDF
5. Single Center Analysis of Bloodstream Infection Clinical Characteristics and Prognosis in Patients with Hematological Malignancies in the Tropics.
- Author
-
CHENG Long-Can, YANG Ting, KUANG Hui-Hui, YU Shuai, GUAN Li-Xun, GU Zhen-Yang, XU Yuan-Yuan, ZHENG Wen-Shuai, WANG Lu, HU Ya-Lei, GAO Xiao-Ning, and WANG Quan-Shun
- Published
- 2021
- Full Text
- View/download PDF
6. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique.
- Author
-
Wang, Rui‐Qi, Chen, Chong‐Jian, Jing, Yu, Qin, Jia‐Yue, Li, Yan, Chen, Guo‐Feng, Zhou, Wei, Li, Yong‐Hui, Wang, Juan, Li, Da‐Wei, Zhao, Hong‐Mei, Wang, Bian‐Hong, Wang, Li‐Li, Wang, Hong, Wang, Meng‐Zhen, Gao, Xiao‐Ning, and Yu, Li
- Subjects
ACUTE myeloid leukemia ,NUCLEOTIDE sequencing ,GENETIC mutation ,PROGNOSIS ,UNIVARIATE analysis ,PRELEUKEMIA ,DISEASE remission - Abstract
To explore the characteristics and prognostic significance of genetic mutations in acute myeloid leukemia (AML), we screened the gene mutation profile of 171 previously untreated AML patients using a next‐generation sequencing technique targeting 127 genes with potential prognostic significance. A total of 390 genetic alterations were identified in 149 patients with a frequency of 87.1%. Younger age and high sensitivity to induction chemotherapy were associated with a lower number of mutations. NPM1 mutation was closely related to DNMT3A and FLT3‐internal tandem duplication (FLT3‐ITD) mutations, but mutually exclusive with ASXL1 mutation and CEBPAdouble mutation. In univariate analysis, ASXL1 or TET2 mutation predicted shorter overall survival (OS) or relapse‐free survival (RFS), DNMT3A, FLT3‐ITD, or RUNX1 mutation predicted a higher likelihood of remission‐induction failure, whereas NRAS mutation or CEBPAdouble mutation predicted longer OS. Concurrent DNMT3A, FLT3‐ITD, and NPM1 mutations predicted shorter OS. Hypomethylation agents could improve the OS in patients with DNA methylation‐related mutations. According to multivariate analysis, TET2 mutation was recognized as an independent prognostic factors for RFS. In summary, our study provided a detailed pattern of gene mutations and their prognostic relevance in Chinese AML patients based on targeted next‐generation sequencing screening. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
- Author
-
Gao, Xiao-Ning, Lin, Ji, Wang, Li-Jun, Li, Fei, Li, Hong-Hua, Wang, Shu-Hong, Huang, Wen-Rong, Gao, Chun-Ji, Yu, Li, and Liu, Dai-Hong
- Subjects
HEMATOLOGIC malignancies ,HEMATOPOIETIC stem cell transplantation ,DISEASE remission ,STEM cell transplantation ,EPSTEIN-Barr virus ,CYTOMEGALOVIRUS diseases ,CYTOMEGALOVIRUSES ,HOMOGRAFTS ,RETROSPECTIVE studies ,PROGNOSIS - Abstract
In allogeneic hematopoietic stem cell transplantation recipients, cytomegalovirus (CMV) infection can cause overt CMV-associated disease, which is a main cause of transplantation-associated mortality. CMV infection correlates closely with donor's type. We therefore examined whether risk factors of CMV reactivation and clinical endpoints in patients with hematologic malignancies after allogeneic peripheral blood stem cell transplantation (PBSCT) differed between using matched-sibling donors (MSD-SCT) and haploidentical donors (HID-SCT). In this retrospective cohort study, we enrolled in 200 consecutive patients received an unmanipulated G-CSF-mobilized allogeneic PBSCT. Ninety (45%) patients received MSD-SCT and 110 (55%) received HID-SCT. Quantitative PCR was used for monitoring of CMV reactivation after transplantation. One-year cumulative incidence of CMV DNAemia was 55.0%, ranging from 23.5% in MSD-SCT group to 81.0% in HID-SCT group (p < 0.001). Although univariate analyses showed that non-myeloid malignancies, disease in complete remission status at transplantation, pretreatment with antithymocyte globulin, HLA-haploidentical donors, male donors, previous Epstein-Barr virus DNAemia, and absolute lymphocyte count on day 30 < 0.6 × 109/L were respectively associated with CMV reactivation after transplantation in total cohort of recipients (all p < 0.05), haploidentical donors were found to be the only independent predictor in multivariate analyses (Hazard ratio = 6.4, p < 0.001). Furthermore, univariate analyses revealed that non-myeloid malignancies and previous Epstein-Barr virus DNAemia were respectively associated with CMV reactivation in MSD-SCT recipients, and female was associated with CMV reactivation in HID-SCT recipients (all p < 0.05). In HID-SCT recipients, but not MSD-SCT recipients, previous CMV DNAemia was associated with a lower cumulative incidence of acute graft-versus-host disease (49.2% vs. 72.6%, p < 0.001). CMV DNAemia did not play a role in the relapse rate, but it was strongly associated with an increased risk of non-relapse mortality either in total cohort of recipients (30.5% vs. 13.7%; p = 0.003) or in the HID-SCT subgroup (36.0% vs. 16.7%; p = 0.030). Relapse-free survival and overall survival in total cohort of recipients with CMV DNAemia were both inferior to those without CMV DNAemia (45.3% vs. 57.6% and 54.8% vs. 65.8%, respectively; both p < 0.05). However, in subgroup analysis according to donor's type, neither relapse-free survival nor overall survival was impacted by CMV status (both p > 0.05). This study addressed differences in incidence, risk factors, and associations with clinical outcomes of CMV reactivation after haploidentical versus matched-sibling PBSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
- Author
-
Gao, Xiao-Ning, Lin, Ji, Wang, Li-Jun, Li, Fei, Li, Hong-Hua, Wang, Shu-Hong, Huang, Wen-Rong, Gao, Chun-Ji, Yu, Li, and Liu, Dai-Hong
- Abstract
In allogeneic hematopoietic stem cell transplantation recipients, reactivation of Epstein-Barr virus (EBV) can cause post-transplantation lymphoproliferative disorder (PTLD), which may rapidly progress to multiorgan failure and even death. Development of EBV PTLD correlates very closely with use of anti-thymocyte globulin (ATG) and type of transplant. To assess the incidences and clinical features of EBV DNAemia and PTLD in the setting of stem cell transplantation using unmanipulated G-CSF-primed allogeneic peripheral blood stem cells as graft, we performed a retrospective analysis of stem cell transplantation from HLA-matched sibling donors (MSD-SCT, n = 90) or HLA-haploidentical related donors (HID-SCT, n = 110) in patients with hematological malignancies. All of HID-SCT recipients and 27.8% of MSD-SCT recipients received an ATG-containing conditioning regimen. One-year cumulative incidence of EBV DNAemia was 44.1%, ranging from 4.8% in MSD-SCT recipients not using ATG to 20.0% in MSD-SCT recipients using ATG, and 73.7% in HID-SCT recipients. Risk factors for EBV reactivation included use of ATG (p = 0.008), male donor (p = 0.034), and cytomegalovirus DNAemia (p < 0.001). One-year incidence of EBV PTLD was 11.9%, ranging from 1.8% in recipients of MSD-SCT not using ATG to 4.4% in recipients of MSD-SCT using ATG, and 23.5% in recipients of HID-SCT. Risk factors for PTLD after HID-SCT included in fludarabine-containing conditioning regimen (p = 0.010), cytomegalovirus DNAemia (p = 0.036), and patient's age < 40-yr (p = 0.032). Two-year non-relapse mortality was higher for patients with EBV DNAemia than those without EBV DNAemia (35.8% vs. 15.3%, p = 0.002). One-year relapse-free survival and overall survival among patients with PTLD were 40.2% and 44.9%, respectively, as opposed to 63.4% and 68.4% among patients without PTLD (both p < 0.05). In multivariate analyses, EBV DNAemia predicted a lower risk of relapse (p = 0.025), while PTLD was a marginally significant predictor of relapse (p = 0.092). This study identified patients at risk of EBV reactivation and PTLD after unmanipulated allogeneic peripheral blood stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
- Author
-
Gao, Xiao-Ning, Lin, Ji, Wang, Li-Jun, Li, Fei, Li, Hong-Hua, Wang, Shu-Hong, Huang, Wen-Rong, Gao, Chun-Ji, Yu, Li, and Liu, Dai-Hong
- Subjects
ACUTE myeloid leukemia ,HEMATOPOIETIC stem cell transplantation ,STEM cell transplantation ,LYMPHOCYTES ,GRAFT versus host disease ,ACUTE myeloid leukemia treatment ,PROTEIN metabolism ,AGE distribution ,SIBLINGS ,CLINICAL trials ,COMPARATIVE studies ,RED blood cell transfusion ,HOMOGRAFTS ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,ORGAN donors ,PROGNOSIS ,PROTEINS ,RESEARCH ,SAFETY ,EVALUATION research ,RETROSPECTIVE studies ,ACUTE diseases ,THERAPEUTICS - Abstract
Donor lymphocyte infusion (DLI) might be used prophylactically to reduce relapse after allogeneic hematopoietic stem cell transplantation for very high-risk leukemia/lymphoma without effective targeted therapy. To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective analysis in a cohort of 21 HID-SCT and 13 MSD-SCT recipients, displaying similar baseline characteristics except for donor's gender distribution. Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59.5% vs. 30.8%, p = 0.05). The grade 3-4 acute GVHD (17.5% vs. 7.7%), 1-year chronic GVHD (36.6% vs. 33.2%), and severe chronic GVHD (15.3% vs. 27.3%) were not statistically significant different between groups. One-year non-relapse mortality was higher in HID-SCT group than that in MSD-SCT group with marginal significance (27.9% vs. 0.0%, p = 0.061). One-year relapse rate was not statistically significant different between HID-SCT group and MSD-SCT group (21.6% vs. 36.5%, p = 0.543). For HID-SCT recipients, 1-year relapse rate was lower in patients receiving prophylactic DLI than that in a control cohort of eight patients with same very high-risk features but not receiving prophylactic DLI (62.5% vs. 28.3%, p = 0.037). No statistically significant difference was observed in 1-year overall survival (OS, 55.1% vs. 83.9%, p = 0.325) and relapse-free survival (RFS, 50.1% vs. 74.0%, p = 0.419) rates between HID-SCT group and MSD-SCT group. In multivariate analyses, non-remission status prior to transplant, poor-risk gene mutations, and donor's age ≥ 48 years predicted a higher risk of relapse after DLI. Non-remission status prior to transplant predicted inferior OS and RFS. Patient's age ≥ 40 years also predicted an inferior OS. In conclusion, prophylactic DLI was very safe and efficient for reducing relapse in patients with very high-risk AML receiving MSD-SCT. In the recipients of HID-SCT, the application of prophylactic DLI could reduce the risk of relapse, although with a higher incidence of DLI-associated acute GVHD than those of MSD-SCT. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
- Author
-
Gao, Xiao-Ning, Wang, Shu-Hong, Huang, Wen-Rong, Li, Fei, Li, Hong-Hua, Chen, Jing, Wang, Li-Jun, Gao, Chun-Ji, Yu, Li, Liu, Dai-Hong, and Lin, Ji
- Subjects
GRAFT versus host disease prevention ,BLOOD donors ,CLINICAL trials ,COMPARATIVE studies ,RED blood cell transfusion ,GRAFT versus host disease ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,LEUKEMIA ,LYMPHOMAS ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,PROGNOSIS ,PROTEINS ,RESEARCH ,DISEASE relapse ,EVALUATION research ,DISEASE incidence ,RETROSPECTIVE studies ,PREVENTION - Abstract
Unmanipulated haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2, and DNMT3a. In this study, we aimed to establish the tolerance and efficacy of prophylactic donor lymphocyte infusion (DLI) with G-CSF-primed peripheral blood progenitors for prevention of relapse in these very high-risk patients after haplo-PBSCT. The prophylactic DLI was given at a median of 77 days after transplantation in 31 of 45 consecutive patients with very high-risk leukemia/lymphoma. The median dose of CD3+ cells for infusion was 1.8 × 107/kg. The 100-day incidences of acute graft-versus-host disease (GVHD) grades 2-4 and 3-4 after DLI were 55.3% and 10.2%. The 2-year incidences of chronic GVHD and severe chronic GVHD were 52.0% and 18.2%. The 2-year incidences of non-relapse mortality and relapse were 33.1% and 32.5%. The 2-year probabilities of overall survival and relapse-free survival were 40.1% and 31.9%. Poor-risk gene mutations (p = 0.029), disease in non-remission status prior to transplantation (p = 0.005), and donors older than 40 years of age (p = 0.043) were associated with relapse after DLI. In multivariate analysis, disease in non-remission status prior to transplantation was an independent risk factor of relapse (hazard ratio = 4.079; p = 0.035). These data showed the feasibility of the prophylactic DLI in the haplo-PBSCT setting and the anti-leukemic efficacy in very high-risk leukemia/lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
- Author
-
Gong, Dan, Li, Wei, Hu, Liang-Ding, Shen, Jian-Liang, Fang, Mei-Yun, Yang, Qing-Ming, Wang, Heng-Xiang, Ke, Xiao-Yan, Chen, Hui-Ren, Wang, Zhao, Liu, Hui, Liu, Feng, Ma, Yi-Gai, Wang, Jing-Wen, Li, Hong-Hua, Wang, Quan-Shun, Jing, Yu, Gao, Xiao-Ning, Dou, Li-Ping, and Li, Yong-Hui
- Subjects
ACUTE myeloid leukemia treatment ,CYTARABINE ,DRUG efficacy ,DISEASES in adults ,RETROSPECTIVE studies - Abstract
Background: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries. Patients: We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation chemotherapy only. Results: The 5-year overall survival (OS) of the high-dose Ara-c group (HDAC; 2≤ Ara-c ≤3 g/m
2 ), intermediate-dose Ara-c group (MDAC; 1.0≤ Ara-c <2.0 g/m2 ), low-dose Ara-c group (LDAC; 0.2< Ara-c <1.0 g/m2 ) and standard-dose Ara-c group (SDAC; 0.1≤ Ara-c ≤0.2 g/m2 ) were 65.3, 39.4, 25.2 and 27.9%, respectively (p = 0.003). In the HDAC group, but not in the MDAC group, the 5-year OS of patients who achieved 3-4 cycles of chemotherapy was superior to those who underwent 1-2 cycles (84.4 vs. 43.6%, p < 0.05), and the 3-year OS of patients who achieved an accumulated 36 g/m2 of Ara-c was significantly higher compared to those who did not (85.3 vs. 39.2%, p < 0.05). Multivariate analysis indicated that factors such as WBC >3.5 × 109 /l, PLT ≤30 × 109 /l, and extramedullary infiltration were associated with a poor prognosis. Conclusion: The survival of t(8;21) AML patients treated with high-dose Ara-c (≥2 g/m2 ) was superior to other dose levels in postremission consolidation chemotherapy. Patient survival was improved by 3-4 cycles of chemotherapy with an accumulated concentration of 36 g/m2 of Ara-c. WBC >3.5 × 109 /l, PLT ≤30 × 109 /l and extramedullary infiltration could be indicative of a poor clinical prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Supra-amphiphilic aggregates formed by p-sulfonatocalix[4]arenes and the antipsychotic drug chlorpromazine.
- Author
-
Qin, Zhanbin, Guo, Dong-Sheng, Gao, Xiao-Ning, and Liu, Yu
- Published
- 2014
- Full Text
- View/download PDF
13. Sevoflurane preconditioning prevents acute renal injury caused by ischemia-reperfusion in mice via activation of the Nrf2 signaling pathway.
- Author
-
Wang, Wen-Xi, Zhao, Zhen-Ru, Bai, Ying, Li, Ya-Xing, Gao, Xiao-Ning, Zhang, Sen, and Sun, Yan-Bin
- Subjects
NUCLEAR factor E2 related factor ,WESTERN immunoblotting ,REPERFUSION injury ,CELLULAR signal transduction ,SEVOFLURANE ,ACUTE kidney failure - Abstract
Oxidative stress, caused by renal ischemia reperfusion (IR)/hypoperfusion, is one of the main causes of acute kidney injury (AKI). Previous studies have demonstrated that sevoflurane (SEV) protects organs from the damage caused by oxidative stress. In the present study, mice were randomly assigned to a sham operation group (Sham), IR-vehicle group (IR+ vehicle), IR + SEV low-dose preconditioning group and an IR + SEV high-dose preconditioning group. The effect of SEV on nuclear factor E2-related factor 2 (Nrf2), a key regulatory protein of the endogenous antioxidant defense system and, consequently oxidative stress, inflammation and apoptosis-related factors, were all quantified using commercial kits or by western blotting. SEV preconditioning was demonstrated to ameliorate kidney injury as a result of decreased blood urine nitrogen and serum creatinine levels, activated Nrf2 expression in the kidney and decreased oxidative stress and inflammatory index levels an AKI mouse model. SEV preconditioning also protected injured kidney via the downregulation of caspase-3 protein expression levels. In addition, using the Nrf2 inhibitor, Brusatol, significantly abolished the SEV preconditioning renal protective effect. Using an in vitro HK-2 cell model of hypoxia/reoxygenation, it was also demonstrated that Nrf2 pathway activation was necessary for SEV to exert its beneficial effect for tubular cell injury caused by hypoxia/reoxygenation. These results indicated that SEV may protect against renal injury caused by IR via Nrf2 upregulation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
- Author
-
Wang, Li-Xin, Mei, Zhen-Yang, Zhou, Ji-Hao, Yao, Yu-Shi, Li, Yong-Hui, Xu, Yi-Han, Li, Jing-Xin, Gao, Xiao-Ning, Zhou, Min-Hang, Jiang, Meng-Meng, Gao, Li, Ding, Yi, Lu, Xue-Chun, Shi, Jin-Long, Luo, Xu-Feng, Wang, Jia, Wang, Li-Li, Qu, Chunfeng, Bai, Xue-Feng, and Yu, Li
- Subjects
DRUG dosage ,GENE expression ,CD80 antigen ,CANCER cells ,CYTOTOXIC T cells ,IMMUNOGENETICS ,DECITABINE - Abstract
Lack of immunogenicity of cancer cells has been considered a major reason for their failure in induction of a tumor specific T cell response. In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model. C57BL/6 mice with established EL4 tumors were treated with DAC (1.0 mg/kg body weight) once daily for 5 days. We found that DAC treatment resulted in infiltration of IFN-γ producing T lymphocytes into tumors and caused tumor rejection. Depletion of CD8
+ , but not CD4+ T cells resumed tumor growth. DAC-induced CTL response appeared to be elicited by the induction of CD80 expression on tumor cells. Epigenetic evidence suggests that DAC induces CD80 expression in EL4 cells via demethylation of CpG dinucleotide sites in the promoter of CD80 gene. In addition, we also showed that a transient, low-dose DAC treatment can induce CD80 gene expression in a variety of human cancer cells. This study provides the first evidence that epigenetic modulation can induce the expression of a major T cell co-stimulatory molecule on cancer cells, which can overcome immune tolerance, and induce an efficient anti-tumor CTL response. The results have important implications in designing DAC-based cancer immunotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
15. A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells.
- Author
-
Gao, Xiao-ning, Lin, Ji, Ning, Qiao-yang, Gao, Li, Yao, Yu-shi, Zhou, Ji-hao, Li, Yong-hui, Wang, Li-li, and Yu, Li
- Subjects
HISTONE acetyltransferase ,CELL cycle ,APOPTOSIS ,ACUTE myeloid leukemia ,CANCER cells ,CHIMERIC proteins ,GENE expression ,MOLECULAR biology ,CANCER treatment - Abstract
AML1-ETO fusion protein (AE) is generated by t(8;21)(q22;q22) chromosomal translocation, which is one of the most frequently observed structural abnormalities in acute myeloid leukemia (AML) and displays a pivotal role in leukemogenesis. The histone acetyltransferase p300 promotes self-renewal of leukemia cells by acetylating AE and facilitating its downstream gene expression as a transcriptional coactivator, suggesting that p300 may be a potential therapeutic target for AE-positive AML. However, the effects of p300 inhibitors on leukemia cells and the underlying mechanisms have not been extensively investigated. In the current study, we analyzed the anti-leukemia effects of C646, a selective and competitive p300 inhibitor, on AML cells. Results showed that C646 inhibited cellular proliferation, reduced colony formation, evoked partial cell cycle arrest in G1 phase, and induced apoptosis in AE-positive AML cell lines and primary blasts isolated from leukemic mice and AML patients. Nevertheless, no significant inhibitory effects were observed in granulocyte colony-stimulating factor-mobilized normal peripheral blood stem cells. Notably, AE-positive AML cells were more sensitive to lower C646 doses than AE-negative ones. And C646-induced growth inhibition on AE-positive AML cells was associated with reduced global histone H3 acetylation and declined c-kit and bcl-2 levels. Therefore, C646 may be a potential candidate for treating AE-positive AML. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Saccharothrix yanglingensis sp. nov., an antagonistic endophytic actinomycete isolated from cucumber plant.
- Author
-
Yan, Xia, Huang, Li-Li, Tu, Xuan, Gao, Xiao-Ning, and Kang, Zhen-Sheng
- Abstract
An endophytic actinomycete strain, designated Hhs.015, was isolated from roots of cucumber seedlings. The endophytic isolate was identified by means of a polyphasic taxonomic approach. On the basis of 16S rRNA gene sequence similarities, strain Hhs.015 was closely related to members of the genus Saccharothrix. DNA-DNA hybridization with the four closest relatives, Saccharothrix longispora NRRL B-16116, Saccharothrix xinjiangensis NRRL B-24321, Saccharothrix autraliensis CGMCC 4.1355 and Saccharothrix espanaensis CGMCC 4.1714, gave similarity values of 33.8, 28.2, 44.1 and 29.5%, respectively, which indicated that strain Hhs.015 represents a novel species of the genus Saccharothrix. This is consistent with the morphological, physiological and chemotaxonomic data. As a whole, these results suggest that strain Hhs.015 represents a novel Saccharothrix species. The name Saccharothrix yanglingensis sp. nov. is proposed, with the type strain Hhs.015 (=CGMCC 4.5627 = KCTC 19722). [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. Effect of CpG Island Methylation on MicroRNA Expression in the k-562 Cell Line.
- Author
-
Yang, Yang, Wang, Li-Li, Li, Yong-Hui, Gao, Xiao-Ning, Liu, Yang, and Yu, Li
- Subjects
METHYLATION ,MICRORNA ,CELL lines ,BIOINFORMATICS ,POLYMERASE chain reaction - Abstract
To test the hypothesis that methylation of a CpG island is associated with regulation of microRNA expression, we investigated CpG islands in the upstream sequences of microRNA precursors (pre-miRNAs) through bioinformatic analysis and determined whether the CpG islands were methylated by methylation-specific PCR in the k-562 cell line. We used 5-azacytidine for DNA demethylation, and changes in microRNA expression were detected by microarray assay, RT-PCR, and real-time PCR after 5-azacytidine induction. We showed that the CpG islands in the upstream regions of 18 pre-miRNAs were methylated, including miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation. Expression levels of miR-369, miR-615, and miR-410 were not regulated by DNA methylation in this cell line. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Effect of microRNA-193b on C-KIT Protien Expression and Biological Behaviors of K562 Cells.
- Author
-
Gao Xiao-Ning, Lin Ji, Gao Li, Ding Yi, Li Jing-Xin, Wang Li-Li, and Yu Li
- Published
- 2011
19. Expression Level of miRNA-663 in Different Leukemic Cell Lines and Its Biological Function.
- Author
-
YANG Yang, WANG Li-Li, LI Yong-Hui, GAO Xiao-Ning, and YU Li
- Published
- 2011
20. Construction of FLT3 3'-UTR-Luciferase Reporter Vector and Evaluation of Its Activity.
- Author
-
GAO Xiao-Ning, LIN Ji, LI Yong-Hui, WANG Li-Li, and YU Li
- Published
- 2010
21. Methylation Status of zo-1 Gene Promoter in Acute Leukemia.
- Author
-
WANG Xin-Rong, GAO Xiao-Ning, RANG Hui-Yuan, WANG Li-Li, LI Yong-Hui, and YU Li
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.